Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care

Helix and Veracyte have partnered to expand access to clinically actionable genomic insights in prostate cancer care. The collaboration makes Helix's whole-exome based hereditary cancer test available alongside Veracyte's Decipher Prostate test, enabling a more complete view of each patient's cancer biology and inherited risk. The partnership aims to provide seamless access to genomic insights, improve treatment choices, and inform risk for additional cancers.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced its second-quarter (Q2) 2025 financial results, highlighting robust revenue growth and strategic partnerships. The company reported total revenue of $130.2 million, up 14% year-over-year (YoY), and testing revenue of $122.3 million, also increasing by 14% YoY [1].

Veracyte's Decipher test, which focuses on prostate cancer, showed exceptional growth, with revenue up 24% to $76.3 million and volume increasing by 28% to approximately 25,500 tests. The Afirma test, which focuses on thyroid cancer, also saw revenue growth of 5% to $43.4 million and a volume increase of 8% to approximately 16,950 tests [1].

The company's strategic partnership with Helix has expanded access to clinically actionable genomic insights in prostate cancer care. This collaboration integrates Helix's whole-exome based hereditary cancer test with Veracyte's Decipher Prostate test, providing a more comprehensive view of each patient's cancer biology and inherited risk. The partnership aims to enhance treatment choices and inform risk for additional cancers [2].

Despite the strong financial performance, Veracyte recorded a GAAP net loss of $1.0 million, or 0.8% of revenue, due to one-time impairment charges related to the restructuring of its French subsidiary. However, adjusted EBITDA for the quarter was $35.8 million, representing 27.5% of revenue [1].

Veracyte's full-year 2025 revenue guidance has been raised to $496 million to $504 million, with testing revenue guidance of $477 million to $483 million, representing 14% to 15% YoY growth. The company has also raised adjusted EBITDA guidance to 23.5% of revenue [1].

The company's Q2 2025 financial results demonstrate strong growth and strategic initiatives, positioning it for continued success in the cancer diagnostics market. Investors and financial professionals should closely monitor Veracyte's progress and the potential impact of its partnerships and strategic initiatives.

References:
[1] https://www.biospace.com/press-releases/veracyte-announces-second-quarter-2025-financial-results
[2] https://www.veracyte.com/press-releases/veracyte-and-helix-partner-to-expand-access-to-genomic-insights-in-prostate-cancer-care